Literature DB >> 9167336

Hidradenitis suppurativa--characteristics and consequences.

G B Jemec1, M Heidenheim, N H Nielsen.   

Abstract

The general characteristics of patients with hidradenitis suppurativa have not been previously described in detail. Although rare complications of the disease have been described, little is known of the average impact of hidradenitis suppurativa. We have now aimed to describe the general characteristics of the disease and its impact on patients with an established diagnosis of hidradenitis (n = 68) and compare these with those of an unselected general population sample (n = 523). Pierced earlobes were more common in patients than in the controls (P < 0.02). Female patients were younger (P = 0.0002) and better educated (P < 0.0001), and fewer had been pregnant (P = 0.0006). The median number of treatments prior to referral was two, and an average of 2.7 work days/patient per year were lost due to hidradenitis. The self-reported health of patients was significantly inferior to that of the general population (P < 0.001), mainly because of soreness and restriction of movement. Low-grade hidradenitis suppurativa therefore has a considerable impact on the health of patients. Previously implied associations with the disease such as the use of cosmetics or oral contraceptives, menstrual cycle and body mass index (BMI) were not confirmed in our study, although they may influence the course pre-existing disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9167336     DOI: 10.1111/j.1365-2230.1996.tb00145.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  22 in total

1.  Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa.

Authors:  J S Kirby; M Butt; T King
Journal:  Br J Dermatol       Date:  2019-08-27       Impact factor: 9.302

2.  The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials.

Authors:  J S Kirby; L Thorlacius; B Villumsen; J R Ingram; A Garg; K B Christensen; M Butt; S Esmann; J Tan; G B E Jemec
Journal:  Br J Dermatol       Date:  2019-12-26       Impact factor: 9.302

3.  Proceeding report of the third symposium on Hidradenitis Suppurativa advances (SHSA) 2018.

Authors:  Claudia J Posso-De Los Rios; Akua Sarfo; Mondana Ghias; Raed Alhusayen; Iltefat Hamzavi; Michelle A Lowes; Afsaneh Alavi
Journal:  Exp Dermatol       Date:  2019-04-29       Impact factor: 3.960

4.  Hidradenitis suppurativa and pruritus ani.

Authors:  Theodor Asgeirsson; Robert Nunoo; Martin A Luchtefeld
Journal:  Clin Colon Rectal Surg       Date:  2011-03

5.  Qualitative study shows disease damage matters to patients with hidradenitis suppurativa.

Authors:  Joslyn S Kirby
Journal:  J Am Acad Dermatol       Date:  2016-06       Impact factor: 11.527

Review 6.  Hormonal Contraceptives and Dermatology.

Authors:  Natalie M Williams; Michael Randolph; Ali Rajabi-Estarabadi; Jonette Keri; Antonella Tosti
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

Review 7.  Hidradenitis suppurativa in children and adolescents: a review of treatment options.

Authors:  Peter Riis Mikkelsen; Gregor B E Jemec
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

8.  Development of a Quality-of-Life Measure for Hidradenitis Suppurativa.

Authors:  Mia Sisic; Joslyn S Kirby; Sanwarjit Boyal; Lisa Plant; Chelsea McLellan; Jerry Tan
Journal:  J Cutan Med Surg       Date:  2016-11-12       Impact factor: 2.092

9.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

Review 10.  Hidradenitis suppurativa.

Authors:  Robert Sabat; Gregor B E Jemec; Łukasz Matusiak; Alexa B Kimball; Errol Prens; Kerstin Wolk
Journal:  Nat Rev Dis Primers       Date:  2020-03-12       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.